Last update: Oct. 15, 2016

Cefuroxime

Very Low Risk for breastfeeding


Safe. Compatible.
Minimal risk for breastfeeding and infant.

Second-generation cephalosporin for oral and injection or parenteral administration.

Like most cephalosporins for which data are available, excretion occurs in breast milk in very small amount and it is clinically insignificant (Voropaeva 1982, Amiraslanova 1985, Nakamura 1987). No adverse effects reported in breasted infants (Benyamini 2005).

Intravenously administered Cefuroxime salt is not orally absorbed.

Cephalosporins are widely used in the Pediatric practice with a good tolerance, even in the neonatal period, so it is very unlikely that in small amounts through milk would be a cause of problems in the infant.

Be aware of the possibility of false negative results of cultures in febrile infants whose mothers are taking antibiotics as well as the possibility of gastroenteritis (Ito 1993) by altering the intestinal flora.

Alternatives

We do not have alternatives for Cefuroxime since it is relatively safe.

Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

Cefuroxime is also known as


Cefuroxime in other languages or writings:

Group

Cefuroxime belongs to this group or family:

Tradenames

Main tradenames from several countries containing Cefuroxime in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 30 - 50 %
Molecular weight 424 daltons
Protein Binding 35 - 50 %
VD 0,33 l/Kg
Tmax 0,75 - 3 hours
T1/2 1,1 - 1,5 hours
Theoretical Dose 0,22 mg/Kg/d
Relative Dose 1,3 - 2,6 %
Relat.Ped.Dose 0,2 %

References

  1. Rowe H, Baker T, Hale TW. Maternal medication, drug use, and breastfeeding. Pediatr Clin North Am. 2013 Feb;60(1):275-94. Abstract
  2. Benyamini L, Merlob P, Stahl B, Braunstein R, Bortnik O, Bulkowstein M, Zimmerman D, Berkovitch M. The safety of amoxicillin/clavulanic acid and cefuroxime during lactation. Ther Drug Monit. 2005 Abstract
  3. Ito S, Blajchman A, Stephenson M, Eliopoulos C, Koren G. Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal medication. Am J Obstet Gynecol. 1993 May;168(5):1393-9. Abstract
  4. Powell DA, James NC, Ossi MJ, Nahata MC, Donn KH. Pharmacokinetics of cefuroxime axetil suspension in infants and children. Antimicrob Agents Chemother. 1991 Abstract Full text (in our servers)
  5. Vree TB, Hekster YA. Pharmacokinetics and tissue concentrations of cefuroxime. Pharm Weekbl Sci. 1990 Abstract
  6. Nakamura T, Hashimoto I, Sawada Y, Mikami J. [Clinical studies on cefuroxime axetil in acute mastitis]. Jpn J Antibiot. 1987 Abstract
  7. Voropaeva SD, Emel'ianova AI, Ankirskaia AS, Minasova GS, Saakian SS. [Effectiveness of using cefuroxime in the obstetrics and gynecology clinic]. Antibiotiki. 1982 Abstract

Total visits

142,681

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write to us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana from Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM